An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs Tipifarnib (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms THoMAS
- 31 Aug 2018 Biomarkers information updated
- 06 Aug 2018 Status changed from not yet recruiting to recruiting, according to Kura oncology media release.
- 06 Aug 2018 According to a Kura Oncology media release the dosing of the first patient is done.